External quality assessment of Rift Valley fever diagnosis in countries at risk of the disease: African, Indian Ocean and Middle-East regions.
Africa
/ epidemiology
Animals
Antibodies, Viral
/ blood
Endemic Diseases
/ veterinary
Enzyme-Linked Immunosorbent Assay
/ standards
Humans
Immunoglobulin G
/ blood
Indian Ocean
/ epidemiology
Laboratories
/ standards
Middle East
/ epidemiology
Quality Assurance, Health Care
Reproducibility of Results
Rift Valley Fever
/ diagnosis
Rift Valley fever virus
/ immunology
Risk Factors
Serologic Tests
/ standards
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
01
2021
accepted:
23
04
2021
entrez:
19
5
2021
pubmed:
20
5
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Rift Valley fever virus (RVFV), an arbovirus belonging to the Phlebovirus genus of the Phenuiviridae family, causes the zoonotic and mosquito-borne RVF. The virus, which primarily affects livestock (ruminants and camels) and humans, is at the origin of recent major outbreaks across the African continent (Mauritania, Libya, Sudan), and in the South-Western Indian Ocean (SWIO) islands (Mayotte). In order to be better prepared for upcoming outbreaks, to predict its introduction in RVFV unscathed countries, and to run efficient surveillance programmes, the priority is harmonising and improving the diagnostic capacity of endemic countries and/or countries considered to be at risk of RVF. A serological inter-laboratory proficiency test (PT) was implemented to assess the capacity of veterinary laboratories to detect antibodies against RVFV. A total of 18 laboratories in 13 countries in the Middle East, North Africa, South Africa, and the Indian Ocean participated in the initiative. Two commercial kits and two in-house serological assays for the detection of RVFV specific IgG antibodies were tested. Sixteen of the 18 participating laboratories (88.9%) used commercial kits, the analytical performance of test sensitivity and specificity based on the seroneutralisation test considered as the reference was 100%. The results obtained by the laboratories which used the in-house assay were correct in only one of the two criteria (either sensitivity or specificity). In conclusion, most of the laboratories performed well in detecting RVFV specific IgG antibodies and can therefore be considered to be prepared. Three laboratories in three countries need to improve their detection capacities. Our study demonstrates the importance of conducting regular proficiency tests to evaluate the level of preparedness of countries and of building a network of competent laboratories in terms of laboratory diagnosis to better face future emerging diseases in emergency conditions.
Identifiants
pubmed: 34010292
doi: 10.1371/journal.pone.0251263
pii: PONE-D-21-03249
pmc: PMC8133482
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0251263Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Emerg Infect Dis. 2002 Dec;8(12):1415-20
pubmed: 12498657
Arch Virol. 2017 Aug;162(8):2505-2538
pubmed: 28434098
PLoS Negl Trop Dis. 2019 May 3;13(5):e0007296
pubmed: 31050673
J Clin Microbiol. 2018 May 25;56(6):
pubmed: 29563201
Clin Infect Dis. 2003 Oct 15;37(8):1084-92
pubmed: 14523773
PLoS Negl Trop Dis. 2017 Apr 3;11(4):e0005427
pubmed: 28369139
PLoS Negl Trop Dis. 2016 Jun 22;10(6):e0004783
pubmed: 27331402
Emerg Infect Dis. 2020 Dec;26(12):3030-3033
pubmed: 33219787
Emerg Infect Dis. 2010 Jun;16(6):963-70
pubmed: 20507747
PLoS One. 2012;7(4):e35216
pubmed: 22539961
Med Vet Entomol. 2002 Sep;16(3):245-52
pubmed: 12243225
PLoS Negl Trop Dis. 2013 May 23;7(5):e2244
pubmed: 23717706
PLoS One. 2018 Jan 24;13(1):e0191565
pubmed: 29364989
PLoS One. 2015 Nov 13;10(11):e0142129
pubmed: 26566248
EFSA J. 2020 Mar 06;18(3):e06041
pubmed: 33020705
Emerg Infect Dis. 2020 Apr;26(4):769-772
pubmed: 32186500
Pathogens. 2020 Dec 11;9(12):
pubmed: 33322276
PLoS Negl Trop Dis. 2017 Sep 15;11(9):e0005936
pubmed: 28915240
Res Virol. 1991 Nov-Dec;142(6):475-82
pubmed: 1687082
Onderstepoort J Vet Res. 2020 Apr 08;87(1):e1-e7
pubmed: 32370521
Vector Borne Zoonotic Dis. 2017 May;17(5):358-360
pubmed: 28437185
Emerg Infect Dis. 2009 Apr;15(4):568-70
pubmed: 19331733
Res Virol. 1989 Jan-Feb;140(1):67-77
pubmed: 2711047
Vet Microbiol. 2008 May 25;129(1-2):80-8
pubmed: 18093755
Res Virol. 1989 Jan-Feb;140(1):27-30
pubmed: 2711042
J Am Vet Med Assoc. 2009 Apr 1;234(7):883-93
pubmed: 19335238
PLoS Negl Trop Dis. 2019 Feb 7;13(2):e0007162
pubmed: 30730887
Biomed Res Int. 2015;2015:678084
pubmed: 26457301
PLoS Negl Trop Dis. 2018 Jul 23;12(7):e0006627
pubmed: 30036382
J Virol Methods. 2013 Jan;187(1):177-81
pubmed: 23022325
PLoS Negl Trop Dis. 2014 Jul 31;8(7):e3045
pubmed: 25078616